Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite BioPharma (NYSEAMERICAN:CANF) Raised to Buy at Zacks Investment Research

January 12, 2022

https://etfdailynews.com/news/can-fite-biopharma-nyseamericancanf-raised-to-buy-at-zacks-investment-research/

Zacks Investment Research upgraded shares of Can-Fite BioPharma (NYSEAMERICAN:CANF) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. The brokerage currently has $1.50 price target on the biotechnology company’s stock.

According to Zacks, “Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company’s lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. “

CANF has been the subject of a number of other reports. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Can-Fite BioPharma in a report on Friday, January 7th. Alliance Global Partners cut their price objective on shares of Can-Fite BioPharma from $9.00 to $8.25 and set a buy rating on the stock in a report on Tuesday, November 30th. They noted that the move was a valuation call.

NYSEAMERICAN:CANF opened at $1.36 on Tuesday. Can-Fite BioPharma has a 1-year low of $0.94 and a 1-year high of $4.39. The stock has a market capitalization of $36.98 million, a P/E ratio of -1.70 and a beta of 1.91.

Can-Fite BioPharma (NYSEAMERICAN:CANF) last announced its earnings results on Tuesday, November 30th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.10). The firm had revenue of $0.25 million during the quarter. Can-Fite BioPharma had a negative return on equity of 183.50% and a negative net margin of 1,518.15%. As a group, analysts anticipate that Can-Fite BioPharma will post -0.56 EPS for the current year.

An institutional investor recently raised its position in Can-Fite BioPharma stock. Morgan Stanley grew its stake in Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) by 131.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 184,775 shares of the biotechnology company’s stock after buying an additional 104,902 shares during the quarter. Morgan Stanley owned 1.07% of Can-Fite BioPharma worth $421,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.17% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for cancer and inflammatory diseases. Its product pipeline includes Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.